Skye Bioscience Stock Forecast

SKYE's stock price has decreased by -67.27% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 8 analysts polled by S&P Global, Skye Bioscience stock has a consensus rating of "Buy" and an average price target of $7.71. The average 1-year stock price forecast is 951.55% higher than the current stock price, while the lowest is $2.00 (+172.78%) and the highest is $20 (+2,627.77%).

Price Target: $7.71 (+951.55%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$7.71	$6.00	$20
Change	+172.78%	+951.55%	+718.33%	+2627.8%

Analyst Ratings

The average analyst rating for Skye Bioscience stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	0	0	0	0	0	0
Buy	4	2	4	4	4	4
Hold	2	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	3	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ananda Ghosh H.C. Wainwright	H.C. Wainwright	Buy Maintains $20	Buy	Maintains	$20	+2,627.77%	May 21, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $13 → $6	Buy	Reiterates	$13 → $6	+718.33%	May 12, 2026
Andy Hsieh William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 12, 2026
Jay Olson Oppenheimer	Oppenheimer	Buy Maintains $10	Buy	Maintains	$10	+1,263.88%	Mar 12, 2026
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Maintains $2	Hold	Maintains	$2	+172.78%	Mar 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.05

from -1.42

EPS Next Year

-1.13

from -1.05

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-7.85M	-18.31M	-13.52M	-30.19M	-58.16M	-46.90M
Net Income	-8.52M	-19.48M	-37.64M	-26.57M	-55.92M	-46.00M
EPS	-	-	-	-	-1.42	-1.05
Free Cash Flow	-3.28M	-9.44M	-11.04M	-9.05M	-22.95M	-41.14M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.05
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-